CH634546A5 - Verfahren zur herstellung von komplexen verbindungen von aminodicarbonsaeuren mit magnesium und halogenen. - Google Patents
Verfahren zur herstellung von komplexen verbindungen von aminodicarbonsaeuren mit magnesium und halogenen. Download PDFInfo
- Publication number
- CH634546A5 CH634546A5 CH1118777A CH1118777A CH634546A5 CH 634546 A5 CH634546 A5 CH 634546A5 CH 1118777 A CH1118777 A CH 1118777A CH 1118777 A CH1118777 A CH 1118777A CH 634546 A5 CH634546 A5 CH 634546A5
- Authority
- CH
- Switzerland
- Prior art keywords
- magnesium
- animals
- halogens
- acids
- complex compounds
- Prior art date
Links
- 239000011777 magnesium Substances 0.000 title claims description 45
- 229910052749 magnesium Inorganic materials 0.000 title claims description 38
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 title claims description 32
- 150000001875 compounds Chemical class 0.000 title claims description 31
- 239000002253 acid Substances 0.000 title claims description 14
- 229910052736 halogen Inorganic materials 0.000 title claims description 6
- 150000007513 acids Chemical class 0.000 title claims description 4
- 150000002367 halogens Chemical class 0.000 title claims description 4
- 238000004519 manufacturing process Methods 0.000 title description 4
- 238000002360 preparation method Methods 0.000 claims description 22
- 239000000243 solution Substances 0.000 claims description 20
- 238000000034 method Methods 0.000 claims description 19
- 239000000203 mixture Substances 0.000 claims description 12
- 239000003513 alkali Substances 0.000 claims description 10
- 235000013918 magnesium diglutamate Nutrition 0.000 claims description 10
- MYUGVHJLXONYNC-UHFFFAOYSA-L magnesium diglutamate Chemical compound [Mg+2].OC(=O)C(N)CCC([O-])=O.OC(=O)C(N)CCC([O-])=O MYUGVHJLXONYNC-UHFFFAOYSA-L 0.000 claims description 10
- 239000004240 magnesium diglutamate Substances 0.000 claims description 10
- -1 magnesium halide Chemical class 0.000 claims description 8
- 238000006243 chemical reaction Methods 0.000 claims description 7
- 150000003839 salts Chemical class 0.000 claims description 7
- 239000007787 solid Substances 0.000 claims description 7
- 229910001508 alkali metal halide Inorganic materials 0.000 claims description 6
- 229910001615 alkaline earth metal halide Inorganic materials 0.000 claims description 6
- 238000001694 spray drying Methods 0.000 claims description 5
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 claims description 3
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 claims description 3
- 239000007864 aqueous solution Substances 0.000 claims description 3
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 claims description 3
- 239000000376 reactant Substances 0.000 claims description 2
- IACWRJKFRODGGM-NVKWYWNSSA-J dimagnesium (2S)-2-aminobutanedioate Chemical compound [Mg+2].[Mg+2].[O-]C(=O)[C@@H](N)CC([O-])=O.[O-]C(=O)[C@@H](N)CC([O-])=O IACWRJKFRODGGM-NVKWYWNSSA-J 0.000 claims 1
- 241001465754 Metazoa Species 0.000 description 37
- 229940091250 magnesium supplement Drugs 0.000 description 31
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 22
- RXMQCXCANMAVIO-CEOVSRFSSA-L magnesium;(2s)-2-amino-4-hydroxy-4-oxobutanoate Chemical compound [H+].[H+].[Mg+2].[O-]C(=O)[C@@H](N)CC([O-])=O.[O-]C(=O)[C@@H](N)CC([O-])=O RXMQCXCANMAVIO-CEOVSRFSSA-L 0.000 description 15
- 241000282887 Suidae Species 0.000 description 14
- 230000037396 body weight Effects 0.000 description 11
- 229910001629 magnesium chloride Inorganic materials 0.000 description 11
- QYOBXHXZJRPWDE-JIZZDEOASA-L magnesium;(2s)-2-amino-4-hydroxy-4-oxobutanoate;chloride Chemical compound [Mg+2].Cl.[O-]C(=O)[C@@H](N)CC([O-])=O QYOBXHXZJRPWDE-JIZZDEOASA-L 0.000 description 11
- 239000000126 substance Substances 0.000 description 11
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 8
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 6
- 241000283690 Bos taurus Species 0.000 description 6
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 6
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 6
- 238000002844 melting Methods 0.000 description 6
- 230000008018 melting Effects 0.000 description 6
- 241000283086 Equidae Species 0.000 description 5
- 235000003704 aspartic acid Nutrition 0.000 description 5
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 5
- 239000000932 sedative agent Substances 0.000 description 5
- 230000001624 sedative effect Effects 0.000 description 5
- 238000011282 treatment Methods 0.000 description 5
- 208000024799 Thyroid disease Diseases 0.000 description 4
- 238000000354 decomposition reaction Methods 0.000 description 4
- 150000004820 halides Chemical class 0.000 description 4
- 210000004185 liver Anatomy 0.000 description 4
- 239000011541 reaction mixture Substances 0.000 description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical class Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 3
- 239000004480 active ingredient Substances 0.000 description 3
- 239000000654 additive Substances 0.000 description 3
- QGBSISYHAICWAH-UHFFFAOYSA-N dicyandiamide Chemical compound NC(N)=NC#N QGBSISYHAICWAH-UHFFFAOYSA-N 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- OTCKOJUMXQWKQG-UHFFFAOYSA-L magnesium bromide Chemical compound [Mg+2].[Br-].[Br-] OTCKOJUMXQWKQG-UHFFFAOYSA-L 0.000 description 3
- 229910001623 magnesium bromide Inorganic materials 0.000 description 3
- 159000000003 magnesium salts Chemical class 0.000 description 3
- IMSNBENJLMCAJL-QTNFYWBSSA-L magnesium;(2s)-2-aminopentanedioate;hydrobromide Chemical compound [Mg+2].Br.[O-]C(=O)[C@@H](N)CCC([O-])=O IMSNBENJLMCAJL-QTNFYWBSSA-L 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 238000002560 therapeutic procedure Methods 0.000 description 3
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 2
- 206010001497 Agitation Diseases 0.000 description 2
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 2
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 2
- JLVVSXFLKOJNIY-UHFFFAOYSA-N Magnesium ion Chemical group [Mg+2] JLVVSXFLKOJNIY-UHFFFAOYSA-N 0.000 description 2
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 150000001298 alcohols Chemical class 0.000 description 2
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 2
- 230000037007 arousal Effects 0.000 description 2
- 230000001914 calming effect Effects 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 239000007795 chemical reaction product Substances 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 238000009826 distribution Methods 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 235000013922 glutamic acid Nutrition 0.000 description 2
- 239000004220 glutamic acid Substances 0.000 description 2
- 229910052739 hydrogen Inorganic materials 0.000 description 2
- 238000011835 investigation Methods 0.000 description 2
- ZLNQQNXFFQJAID-UHFFFAOYSA-L magnesium carbonate Chemical compound [Mg+2].[O-]C([O-])=O ZLNQQNXFFQJAID-UHFFFAOYSA-L 0.000 description 2
- 239000001095 magnesium carbonate Substances 0.000 description 2
- 229910000021 magnesium carbonate Inorganic materials 0.000 description 2
- 229910001425 magnesium ion Inorganic materials 0.000 description 2
- 230000003287 optical effect Effects 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 239000000825 pharmaceutical preparation Substances 0.000 description 2
- IOLCXVTUBQKXJR-UHFFFAOYSA-M potassium bromide Chemical compound [K+].[Br-] IOLCXVTUBQKXJR-UHFFFAOYSA-M 0.000 description 2
- 229940125723 sedative agent Drugs 0.000 description 2
- 238000003307 slaughter Methods 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 238000005303 weighing Methods 0.000 description 2
- NGNBDVOYPDDBFK-UHFFFAOYSA-N 2-[2,4-di(pentan-2-yl)phenoxy]acetyl chloride Chemical compound CCCC(C)C1=CC=C(OCC(Cl)=O)C(C(C)CCC)=C1 NGNBDVOYPDDBFK-UHFFFAOYSA-N 0.000 description 1
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
- 241000251730 Chondrichthyes Species 0.000 description 1
- 229920000742 Cotton Polymers 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 206010061216 Infarction Diseases 0.000 description 1
- 206010052098 Iodine allergy Diseases 0.000 description 1
- 229920000715 Mucilage Polymers 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 206010038743 Restlessness Diseases 0.000 description 1
- 206010039897 Sedation Diseases 0.000 description 1
- NOSIYYJFMPDDSA-UHFFFAOYSA-N acepromazine Chemical compound C1=C(C(C)=O)C=C2N(CCCN(C)C)C3=CC=CC=C3SC2=C1 NOSIYYJFMPDDSA-UHFFFAOYSA-N 0.000 description 1
- 229960005054 acepromazine Drugs 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 150000001342 alkaline earth metals Chemical class 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 229940024606 amino acid Drugs 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 150000001509 aspartic acid derivatives Chemical class 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 229910052794 bromium Inorganic materials 0.000 description 1
- 229910001622 calcium bromide Inorganic materials 0.000 description 1
- 239000001110 calcium chloride Substances 0.000 description 1
- 229910001628 calcium chloride Inorganic materials 0.000 description 1
- WGEFECGEFUFIQW-UHFFFAOYSA-L calcium dibromide Chemical compound [Ca+2].[Br-].[Br-] WGEFECGEFUFIQW-UHFFFAOYSA-L 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 239000012050 conventional carrier Substances 0.000 description 1
- 239000007857 degradation product Substances 0.000 description 1
- 230000001934 delay Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 230000035622 drinking Effects 0.000 description 1
- 238000000921 elemental analysis Methods 0.000 description 1
- 238000011067 equilibration Methods 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 230000009931 harmful effect Effects 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 229940071870 hydroiodic acid Drugs 0.000 description 1
- 230000007574 infarction Effects 0.000 description 1
- 150000002497 iodine compounds Chemical class 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 229960001983 magnesium aspartate Drugs 0.000 description 1
- 150000002681 magnesium compounds Chemical class 0.000 description 1
- WQAQVZMASSANIM-QTNFYWBSSA-L magnesium;(2s)-2-amino-5-hydroxy-5-oxopentanoate;chloride Chemical compound [Mg+2].Cl.[O-]C(=O)[C@@H](N)CCC([O-])=O WQAQVZMASSANIM-QTNFYWBSSA-L 0.000 description 1
- NFFJLMKHRCXLJO-DKWTVANSSA-L magnesium;(2s)-2-aminobutanedioate Chemical compound [Mg+2].[O-]C(=O)[C@@H](N)CC([O-])=O NFFJLMKHRCXLJO-DKWTVANSSA-L 0.000 description 1
- PQJUPEUXKFFHNR-JIZZDEOASA-L magnesium;(2s)-2-aminobutanedioate;hydrobromide Chemical compound [Mg+2].Br.[O-]C(=O)[C@@H](N)CC([O-])=O PQJUPEUXKFFHNR-JIZZDEOASA-L 0.000 description 1
- GWFRUBJRNASZET-JIZZDEOASA-L magnesium;(2s)-2-aminobutanedioate;hydroiodide Chemical compound [Mg+2].I.[O-]C(=O)[C@@H](N)CC([O-])=O GWFRUBJRNASZET-JIZZDEOASA-L 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- 238000006386 neutralization reaction Methods 0.000 description 1
- 230000003472 neutralizing effect Effects 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 239000001103 potassium chloride Substances 0.000 description 1
- 235000011164 potassium chloride Nutrition 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 235000018102 proteins Nutrition 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 229940001470 psychoactive drug Drugs 0.000 description 1
- 239000004089 psychotropic agent Substances 0.000 description 1
- 230000036280 sedation Effects 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 150000005846 sugar alcohols Polymers 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 230000035922 thirst Effects 0.000 description 1
- 230000009974 thixotropic effect Effects 0.000 description 1
- 229940125725 tranquilizer Drugs 0.000 description 1
- 239000003204 tranquilizing agent Substances 0.000 description 1
- 230000002936 tranquilizing effect Effects 0.000 description 1
- 230000004584 weight gain Effects 0.000 description 1
- 235000019786 weight gain Nutrition 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K20/00—Accessory food factors for animal feeding-stuffs
- A23K20/10—Organic substances
- A23K20/142—Amino acids; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K20/00—Accessory food factors for animal feeding-stuffs
- A23K20/20—Inorganic substances, e.g. oligoelements
- A23K20/24—Compounds of alkaline earth metals, e.g. magnesium
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K50/00—Feeding-stuffs specially adapted for particular animals
- A23K50/30—Feeding-stuffs specially adapted for particular animals for swines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Polymers & Plastics (AREA)
- Engineering & Computer Science (AREA)
- Animal Husbandry (AREA)
- Zoology (AREA)
- Food Science & Technology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Inorganic Chemistry (AREA)
- Epidemiology (AREA)
- Birds (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Organic Chemistry (AREA)
- Anesthesiology (AREA)
- Neurosurgery (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Fodder In General (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE2720288A DE2720288C2 (de) | 1977-05-05 | 1977-05-05 | Verwendung von Magnesiumsalzen zur Herstellung von Zubereitungen zur Behandlung von Nutztieren |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CH634546A5 true CH634546A5 (de) | 1983-02-15 |
Family
ID=6008177
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CH1118777A CH634546A5 (de) | 1977-05-05 | 1977-09-13 | Verfahren zur herstellung von komplexen verbindungen von aminodicarbonsaeuren mit magnesium und halogenen. |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US4192865A (OSRAM) |
| JP (1) | JPS5417128A (OSRAM) |
| AT (1) | AT362222B (OSRAM) |
| AU (1) | AU516768B2 (OSRAM) |
| BE (1) | BE866573A (OSRAM) |
| CA (1) | CA1112574A (OSRAM) |
| CH (1) | CH634546A5 (OSRAM) |
| DE (1) | DE2720288C2 (OSRAM) |
| FR (1) | FR2389378B1 (OSRAM) |
| GB (1) | GB1575994A (OSRAM) |
| NL (1) | NL7804626A (OSRAM) |
| NO (1) | NO781505L (OSRAM) |
| NZ (1) | NZ187136A (OSRAM) |
| SE (1) | SE437918B (OSRAM) |
| ZA (1) | ZA782482B (OSRAM) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5505968A (en) * | 1993-07-02 | 1996-04-09 | Her Majesty The Queen In Right Of Canada, As Represented By The Department Of Agriculture | Antemortem nutrient supplement for livestock |
| EP1222861A1 (en) * | 2000-12-22 | 2002-07-17 | Nabuurs Groep B.V. | Preslaughter supplement |
| KR20110084162A (ko) * | 2008-09-18 | 2011-07-21 | 얀센 파마슈티카 엔.브이. | 성장성 향상을 위한 아자페론의 용도 |
| US10271566B2 (en) * | 2013-11-20 | 2019-04-30 | Charles Sturt University | Stress management in livestock |
| WO2015074115A1 (en) | 2013-11-20 | 2015-05-28 | Meat & Livestock Australia Limited | Prevention and treatment of toxicosis |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE1135923B (de) * | 1959-11-05 | 1962-09-06 | M Y F Ferrer & Cia Ltda Lab | Verfahren zur Herstellung von Magnesiumglutamat-Hydrobromid |
| US3836668A (en) * | 1960-12-27 | 1974-09-17 | Ferrer Labor | Therapeutic composition and method of treating patients therewith |
| DE1809121C3 (de) * | 1968-11-15 | 1978-04-27 | Verla-Pharm. Arzneimittelfabrik, Apotheker H.J.V. Ehrlich, 8132 Tutzing | Magnesiummonoaspartat-Hydrobromid und dieses enthaltende Arzneimittel |
| DE1809119C3 (de) * | 1968-11-15 | 1973-12-20 | Verla-Pharm Arzneimittelfabrik, Apotheker H.J.V.Ehrlich, 8132 Tutzing | Infarktprophylaktikum |
| DE2228101C3 (de) * | 1972-06-09 | 1979-07-05 | Verla-Pharm. Arzneimittelfabrik, Apotheker H.J. V. Ehrlich, Gmbh & Co Kg, 8132 Tutzing | Verfahren zur Gewinnung von Komplexverbindungen aus Aminodicarbonsäureionen, Magnesiumionen und Halogenidionen |
| DE2507354A1 (de) * | 1975-02-20 | 1976-09-09 | Verla Pharm | Pharmazeutische zubereitung |
-
1977
- 1977-05-05 DE DE2720288A patent/DE2720288C2/de not_active Expired
- 1977-09-13 CH CH1118777A patent/CH634546A5/de not_active IP Right Cessation
-
1978
- 1978-03-01 ZA ZA00782482A patent/ZA782482B/xx unknown
- 1978-04-21 SE SE7804556A patent/SE437918B/sv not_active IP Right Cessation
- 1978-04-27 US US05/900,568 patent/US4192865A/en not_active Expired - Lifetime
- 1978-04-27 CA CA302,140A patent/CA1112574A/en not_active Expired
- 1978-04-28 NL NL7804626A patent/NL7804626A/xx active Search and Examination
- 1978-04-28 BE BE187281A patent/BE866573A/xx not_active IP Right Cessation
- 1978-04-28 NO NO781505A patent/NO781505L/no unknown
- 1978-05-01 NZ NZ187136A patent/NZ187136A/xx unknown
- 1978-05-02 JP JP5325778A patent/JPS5417128A/ja active Pending
- 1978-05-03 AT AT321878A patent/AT362222B/de not_active IP Right Cessation
- 1978-05-03 AU AU35729/78A patent/AU516768B2/en not_active Expired
- 1978-05-04 GB GB17694/78A patent/GB1575994A/en not_active Expired
- 1978-05-05 FR FR7813309A patent/FR2389378B1/fr not_active Expired
Also Published As
| Publication number | Publication date |
|---|---|
| GB1575994A (en) | 1980-10-01 |
| AU3572978A (en) | 1979-11-08 |
| ATA321878A (de) | 1980-09-15 |
| SE7804556L (sv) | 1978-11-06 |
| SE437918B (sv) | 1985-03-25 |
| NL7804626A (nl) | 1978-11-07 |
| NZ187136A (en) | 1980-12-19 |
| JPS5417128A (en) | 1979-02-08 |
| DE2720288C2 (de) | 1984-02-16 |
| FR2389378B1 (OSRAM) | 1981-11-20 |
| DE2720288A1 (de) | 1978-11-16 |
| AT362222B (de) | 1981-04-27 |
| FR2389378A1 (OSRAM) | 1978-12-01 |
| US4192865A (en) | 1980-03-11 |
| CA1112574A (en) | 1981-11-17 |
| AU516768B2 (en) | 1981-06-18 |
| ZA782482B (en) | 1979-04-25 |
| NO781505L (no) | 1978-11-07 |
| BE866573A (fr) | 1978-08-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE2501787C2 (OSRAM) | ||
| DE2455281C3 (de) | Trockenes, stabiles, pulverförmiges Mittel zur Behandlung von Ruhr und Dehydratisierung sowie Tetanie bei Haustieren (Säugetieren) | |
| EP0188810B1 (de) | Verwendung von Dipeptidderivaten für die Herstellung von Arzneimitteln zur Verhinderung oder Behandlung posttraumatischer Nervenschäden nach unfallbedingten Rückenmarks- und/oder Gehirntraumen | |
| DE2712786A1 (de) | Veterinaerpraeparat | |
| DE69108022T3 (de) | Arzneimittel. | |
| DE2855851C2 (de) | Stabilisierte Addukte von Vitamin-K-Verbindungen mit organischen Verbindungen, Verfahren zu deren Herstellung und deren Verwendung | |
| DE2323187A1 (de) | Verfahren zur herstellung einer stabilisierten, pulverfoermigen secretinzubereitung durch gefriertrocknung | |
| DE10334820A1 (de) | Pharmazeutische Zusammensetzungen mit antibiotischer Aktivität | |
| DE3000743C2 (de) | Arzneipräparat auf der Basis eines Salzes der Acetylsalicylsäure und einer basischen Aminosäure | |
| DE2455203C2 (OSRAM) | ||
| EP4009808B1 (de) | Konzentrat zur herstellung einer tränklösung | |
| DE69619518T2 (de) | Wasserlösliche pulverzusammensetzungen und ihre verwendungen | |
| DE69115102T2 (de) | Stabilisator für eine 4-ethyl-2-hydroxyimino-5-nitro-3-hexenamide enthaltende Zusammensetzung und Stabilisierungsverfahren. | |
| DE1964504C3 (de) | Arzneimittel zur Behandlung ödematöser Zustände und Hypertensionen | |
| DE2314387C3 (de) | Arzneimittel zur Behandlung bösartiger Neubildungen | |
| DE2720288C2 (de) | Verwendung von Magnesiumsalzen zur Herstellung von Zubereitungen zur Behandlung von Nutztieren | |
| DE1086012B (de) | Verfahren zur Herstellung von protrahiert wirkenden Vitamin-B-Praeparaten | |
| DE2102889C3 (de) | Verwendung von SuIf adimidin und Pyrimethamin | |
| DE1944906A1 (de) | Aliphatische Sulfate des Erythromycins | |
| EP2253307B1 (de) | L-Carnitin zur Kristallisationshemmung | |
| DE2030932C3 (de) | Arzneimittel zur oralen Behandlung von Oxalatsteinen | |
| DE1942747C3 (de) | Futtermittelzusatz für junge Ferkel | |
| DE68916409T2 (de) | Magnesiumkaliumcitrat. | |
| DE2600004A1 (de) | Robenidin enthaltende wassersuspendierbare zusammensetzung | |
| DE1792791A1 (de) | Reaktionsprodukt mit antiviraler wirkung, verfahren zu seiner herstellung und arzneimittel |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PL | Patent ceased |